VEC-162 20 mg
VP-VEC-162-3104
Phase 3 small_molecule completed
Quick answer
VEC-162 20 mg for Primary Insomnia is a Phase 3 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vanda Pharmaceuticals
- Indication
- Primary Insomnia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed